7 Undervalued Pharmaceuticals Stocks for Thursday, November 21
Discover the top 7 undervalued Pharmaceuticals stocks for Thursday, November 21 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company’s lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer’s disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Commentary & Analysis
5 Undervalued Pharmaceuticals Stocks for Friday, October 04
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, October 04 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, May 21
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, May 21 based on AAII’s Stock Grades.Grace Malone
3 Undervalued Biotechnology & Medical Research Stocks for Tuesday, April 09
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Tuesday, April 09 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Biotechnology & Medical Research Stocks for Friday, February 16
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Friday, February 16 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | INM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.7 | $569.9 | 5% |
|
| Shares Out (Mil) | 4.0 | 44.8 | 12% |
|
| Institutional Ownership | 34.8% | 84.6% | 15% |
|
| Float (Mil) | 0.8 | 45.1 | 2% |
|
| Beta | 0.97 | 0.67 | 58% |
|
| Avg Daily Volume (000s) | 5,475 | 294 | 93% |
|
| Price Change (52-week) |
(43.8%) | 65.2% | 18% |
|
| Growth | INM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 1.6% | (2.0%) | 42% |
|
| EPS (5yr) | 60.4% | 14.9% | 96 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.0% | (14.9%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | INM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $230 | 6% |
|
| Net Income (TTM) (Mil) | ($9) | ($11) | 30% |
|
| EPS (TTM) | ($2.531) | ($0.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($6) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $2 | $493 | 4% |
|
| Valuation | INM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.89 | 14% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | INM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 34.5% | 65.9% | 42% |
|
| Net Margin | (172.2%) | (0.2%) | 5% |
|
| ROA | (92.4%) | (25.5%) | 6% |
|
| ROE | (122.3%) | (21.4%) | 8% |
|
| Liabilities to Assets | 24.5% | 35.5% | 16% |
|
| F-Score | 2 | 3 | 7% |
|
InMed Pharmaceuticals Inc. did not pass any screens on 7/30/2026.
